

CVS/caremark Updates to Performance Drug List July 1, 2015

CVS/caremark manages multiple drug lists. Within the therapeutic categories represented, identification of preferred drugs may help optimize clinical results and economic value for your patients. The drug lists include preferred products within 80 percent to 90 percent of the top therapeutic categories that affect our clients prescription drug spend. Updates or changes to these lists may affect cost share for your patients.

CVS/caremark may add or remove drugs from our Performance Drug List during the year. If we add/remove drugs from our drug list, we will notify you of the change(s) quarterly. However, if the U.S. Food and Drug Administration deems a drug to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our drug list.

This letter highlights changes to the Performance Drug List effective July 1, 2015.

Products to be added to the Performance Drug List			
celecoxib	clobetasol spray	colchicine tabs	estradiol (transdermal)
fluorouracil			
Products to be removed from the Performance Drug List			
CARAC	CELEBREX	CLOBEX SPRAY	VIVELLE-DOT

Development and management of drug lists are an integral component in the pharmacy benefit management services CVS/caremark provides to health plans and plan sponsors. At the "For Pharmacists and Medical Professionals" page at www.caremark.com you may review the Formulary Development and Management White Paper that more fully describes this process. You may also visit www.caremark.com for the most up-to-date version of our drug lists, www.caremark.com/druglist for a list of drugs that have been removed from our drug lists, and www.caremark.com/padruglist for a list of drugs that require prior authorization for medical necessity.

Note: This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark. Patients' specific prescription benefit plan design may not cover certain drugs, regardless of their appearance in this document. Clients may implement a formulary exception process for patients meeting certain criteria.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution, or copying of it or its contents, is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. This communication is a Caremark Document within the meaning of the Provider Manual.

©2015 CVS/caremark. All rights reserved. This document contains proprietary information of CVS/caremark and cannot be reproduced, distributed or printed without written permission from CVS/caremark.